Document Detail


Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
MedLine Citation:
PMID:  7858506     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite consolidation and/or maintenance chemotherapy most patients with newly diagnosed acute myelogenous leukemia relapse such that only 20-30% survive free of recurrence at five years. To evaluate the long-term effects of dose-intensive consolidation, we analysed 123 consecutive patients, age 16 to 84 (median 48 years), who received high-dose cytarabine-based consolidation chemotherapy. After a median follow-up of 88 months (range 26 to 126 months), 38 patients remain alive, with 26 in continued remission from 45 to 126+ months. Median remission duration for all eligible patients is 14 months (range 1.3 to 126 months) and actuarial leukemia-free survival at five years is 24 +/- 8%. Median survival from remission is 24 months (range 1.3 to 126 months) and actuarial survival from remission is 31 +/- 9%. Eighty-two patients (67%) have relapsed with an actuarial risk of relapse of 71 +/- 9% at five years. Adverse prognostic factors were age over 45 and male gender. When compared to historical controls (P = 0.02), dose-intensive consolidation produced improved leukemia-free survival for patients age < 45, but compliance and enhanced toxicity in the older age groups may limit further dose intensification.
Authors:
G Schiller; J Gajewski; M Lee; W Ho; M Territo; R Champlin
Related Documents :
3890786 - High rate of long-term survival in adult acute leukemia following ten-day chemotherapy ...
1794736 - Continuous-infusion cyclophosphamide plus vincristine, cytosine-arabinoside and prednis...
2084086 - Phycomycosis infection in acute leukaemia.
8839716 - Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leuka...
1963696 - Efficacy of transcatheter arterial embolization therapy for small hepatocellular carcin...
21139886 - Neuroblastoma occurring in a 38-year old nigerian man: a rare finding.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  15     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  1994 Sep 
Date Detail:
Created Date:  1995-03-20     Completed Date:  1995-03-20     Revised Date:  2007-09-04    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  85-90     Citation Subset:  IM    
Affiliation:
Department of Medicine, UCLA School of Medicine 90024.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
California / epidemiology
Cytarabine / administration & dosage*,  adverse effects
Daunorubicin / administration & dosage
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Leukemia, Myeloid / drug therapy*,  mortality
Life Tables
Male
Middle Aged
Mitoxantrone / administration & dosage
Preleukemia / epidemiology
Remission Induction
Survival Analysis
Thioguanine / administration & dosage
Treatment Outcome
Chemical
Reg. No./Substance:
147-94-4/Cytarabine; 154-42-7/Thioguanine; 20830-81-3/Daunorubicin; 65271-80-9/Mitoxantrone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The influence of induction chemotherapy dose and dose intensity on the duration of remission in acut...
Next Document:  EBV gene expression, EBNA antibody responses and EBV+ peripheral blood lymphocytes in post-transplan...